Evidence mapPaperPMID 33909316Full record

ReviewJournal of neuroendocrinology2021

Role of serotonin in body weight, insulin secretion and glycaemic control.

Teodora Georgescu, David Lyons, Lora K Heisler

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of neuroendocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Serotonin Influences Insulin Secretion in Rat Insulinoma INS-1E Cells.International journal of molecular sciences · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Subcortical serotonin 5HTNature communications · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Teodora GeorgescuDepartment of Anatomy, Centre for Neuroendocrinology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.ORCID 0000-0002-4586-8319
David LyonsSchool of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, UK.
Lora K HeislerRowett Institute, University of Aberdeen, Aberdeen, UK.ORCID 0000-0002-7731-1419
University of Aberdeen · GBUniversity of Bristol · GBUniversity of Otago · NZ

Funding

Biotechnology and Biological Sciences Research Council BBN017838/1Biotechnology and Biological Sciences Research Council BB/R01857X/1Diabetes UK 18/0005884
6 · The paper itself

Abstract

Obesity and type 2 diabetes are key healthcare challenges of the 21st century. Subsequent to its discovery in 1948, serotonin (5-hydroxytryptamine; 5-HT) has emerged as a principal modulator of energy homeostasis and body weight, prompting it to be a target of weight loss medications (eg, fenfluramine, D-fenfluramine, fenfluramine-phentermine and sibutramine). The potential risk of off-target effects led to these medications being withdrawn from clinical use and spurred drug discovery into 5-HT receptor selective ligands. The serotonin 2C receptor (5-HT

Indexed as

AnimalsBlood GlucoseBody WeightGlycemic ControlHumansInsulin SecretionSerotoninBlood GlucoseSerotonin5-HTbody weightglycaemic controlinsulinobesityserotonin

Identifiers

PMID33909316
PMCPMC11475328
OpenAlexW3158492777

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.